Original Research Article I Volume 8 I Issue 2 I 2022
Antiviral Potency of HIV Long term Survivors Sera
Muttineni Radhakrishna
The American Journal of Science and Medical Research (2022), 8(2); 12-15
DOI:https://dx.doi.org/10.5281/zenodo.7340286
Abstract:
The survival of a small fraction (5-15%) of individuals without immunologic deterioration after beinginfectedwithHIVformorethan8-10yearswithoutanytherapyisstillelusive. Long-term non-progressors of HIV -1 infected children serve as ideal models to study virological, genetic and immunological characteristics to determine factors associated with slow progression of disease and death due to their natural control of HIV-1 infection. LTNP and LTPs whole blood were collected by venipuncture in CPT tubes. Blood was transported to the lab within 3- 6 hours in a leek-proof container. IgG was purified from the plasma by absorption with protein A- agarose and virus quantified by P24 Assay.Plasmafromallthegroups LTNP, SP, and FPneutralizedor reduced HIV replication above 50% inhibition at low dilutions (10-1).The neutralization was statistically significant (P < 0.01) between LTNP and SP, FP cohort at higher dilutions (10-2to 10-4) whereLTNP (ART Naïve) plasmashowedhigherneutralizationactivitythan SP, FPplasma. 6 non-progressors and 6 fast progressor’s samples were used for evaluation. It showed that plasma from fast progressors could neutralize only one strain NL4-3. No neutralization of the other two isolates HIV-192BR025 and HIV-1 93IN101wasobservedwiththeplasmasfromfastprogressors,whileminimum3samples(50%)of LTNP could neutralize all the 3 isolates and 4 (66.6%) of LTNP neutralized minimum 2 isolates. The neutralization breadth of plasmas from LTNP was greater than FP. Plasmas wereagainre-evaluatedforvirusneutralizationwithbothIg Gandnon-IgGfractions.Flow-through fractions showed only 10 to 20% neutralizing activity, whereas antibody fraction displayed 60 to 80% neutralizing activity.Neutralizing activity of plasma revealed that LTNP had higher levels of neutralizing antibodies and broad neutralization activity against primary isolates and the neutralizing activityof plasma is attributed to antibody IgG fraction. Our results provide some insight into antibody titer and the breadth of neutralization of diseaseprogression.
Keywords:
LTNP, LTP, Neutralization, Ig G and Non Ig G
References:
[1] Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential antiviral immunity in children and adults. Nat Rev Immunol. 2012 Sep;12(9):636-48.
[2] Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol. 1996 Sep 1;157(5):2168-73
[3] Blanche S et al 1990. Longitudinal study of 94 symptomatic infants with perinatally acquired human immuno- deficiency virus infection: Evidence for a biomodal expression of clinical and biological symptoms American Journal of Diseases of Children, 144,1210– 1215.
[4] E L Delwart, H Pan, H W Sheppard, D Wolpert, A U Neumann, B Korber, and J I MullinsSlower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS J Virol. 1997 Oct; 71(10): 7498–7508.
[5] Dyer WB, Geczy AF, Kent SJ, McIntyre LB, Blasdall SA, Learmont JC, Sullivan JS. Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. AIDS. 1997 Nov;11(13):1565-74.
[6] Astrid SamuelssonChristinaBroströmNienkevan Dijk, Anders SönnerborgApoptosis of CD4+and CD19+Cells during Human Immunodeficiency Virus Type 1 Infection—Correlation with Clinical Progression, Viral Load, and Loss of Humoral Immunity. VirologyVolume 238, Issue 2, 24 November 1997, Pages 180-188.
[7] Scott GB, Hutto C, Makuch RW, Mastrucci MT, O'Connor T, Mitchell CD, Trapido EJ, Parks WP. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med. 1989.
[8] S. Tetali, E. Abrams,s. Bakshi, M. Paul,N. Oyaizu, S. Pahwa Virus Load as a Marker of Disease Progression in HIV-infected Children AIDS Research and Human Retro virusesVol. 12, No. 8.
[9] Walker, Neff et al. Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic? The Lancet, Volume 363, Issue 9427, 2180 – 2185
[10] Zhang YJ, Fracasso C, Fiore JR, Björndal A, Angarano G, Gringeri A, Fenyö EM. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis. 1997 Nov;176(5):1180-7.
Article Dates:
Received: 3 April 2022; Accepted: 28 May 2022; Published: 15 June 2022
How To Cite:
https://dx.doi.org/10.5281/zenodo.7340286 Received: 3April 2022; Accepted: 28May 2022; Published: 15 June 2022
